NasdaqGM:LGNDPharmaceuticals
Ligand Pharmaceuticals (LGND) Stock Looks Undervalued On Cash Flow While Earnings Look Overvalued
Ligand Pharmaceuticals stock has delivered a very strong 327.2% return over the past three years, while recent valuation checks point in different directions. A Discounted Cash Flow (DCF) estimate suggests the shares trade below intrinsic value, whereas market multiples indicate a richer valuation.
The 327.2% gain over three years suggests that expectations have reset higher and leaves less room for simple mean reversion arguments to explain the current share price.
Stronger royalty revenue...